Evaxion Biotech (EVAX) has released an update.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Evaxion Biotech reports significant progress in Q3 2024, highlighted by an expanded partnership with Merck and promising clinical results for its personalized cancer vaccine, EVX-01. Despite a cash position of $4.6 million and a net loss reduction, the company faces potential Nasdaq delisting due to equity compliance issues. Evaxion remains confident in its multi-partner strategy to drive future growth and income.
For further insights into EVAX stock, check out TipRanks’ Stock Analysis page.
